Citations Appearing in 2002

  1. Almon, R.R., D.C. DuBois, E.H. Brandenburg, W. Shi, S. Zhang, R.M. Straubinger and W.J. Jusko. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. Journal of Pharmacokinetics and Pharmacodynamics 29(2):103-129, 2002.
  2. Altman, R.B. and T.E. Klein. Challenges for biomedical informatics and pharmacogenomics. Annual Review of Pharmacology and Toxicology 42:113-133, 2002.
  3. Ambrose, P.G., R.C. Owens Jr, M.J. Garvey and R.N. Jones. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. Journal of Antimicrobial Chemotherapy 49(3):445-453, 2002.
  4. Aminimanizani, A., P.M. Beringer, J. Kang, L. Tsang, R.W. Jelliffe and B.J. Shapiro. Distribution and elimination of tobramycin administerd in single or multiple daily doses in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 50(4):553-559, 2002.
  5. Andersson, B.S., P.F. Thall, T. Madden, D. Couriel, X.M. Wang, H.T. Tran, P. Anderlini, M. de Lima, J. Gajewski and R.E. Champlin. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation 8(9):477-485, 2002.
  6. Athale, U.H., C. Stewart, J.F. Kuttesch, A. Moghrabi, W. Meyer, C. Pratt, A. Gajjar and R.L. Heideman. Phase I study of combination topotecan and Carboplatin in pediatric solid tumors. Journal of Clinical Oncology 20(1):88-95, 2002.
  7. Azay, J., J. Bres, M. Krosniak, P.L. Teissedre, J.C. Cabanis, J.J. Serrano and G. Cros. Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulfate to rats. Fundamental and Clinical Pharmacology 15(5):313-324, 2002.
  8. Beringer P., A. Aminimanizani, T. Synold, and C. Scott. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Therapeutic Drug Monitoring 24(2):315-321, 2002.
  9. Bernstein, S.H., W.J. Jusko, W. Krzyanski, J. Nichol and M. Wetzler. Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. Journal of Clinical Pharmacology 42(5):501-511, 2002.
  10. Booker, B.M., M.H. Magee, R.A. Blum, C.D. Lates and W.J. Jusko. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Clinical Pharmacology and Therapeutics 72(4):370-382, 2002.
  11. Callegari, T., A. Caumo and C. Cobelli. Generalization of map estimation in SAAM II: Validation against ADAPT II in a glucose model case study. Annals of Biomedical Engineering 30(7):961-968, 2002.
  12. Chakraborty, A. and W.J. Jusko. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. Journal of Pharmaceutical Sciences 91(5):1334-1342, 2002.
  13. Chow, F.S., L.J. Benincosa, S.B. Sheth, D.Wilson D C.B. Davis E.A. Minthorn and W.J. Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of humanized antifactor IX antibody (SB 249417) in humans. Clinical Pharmacology and Therapeutics 71(4):235-245, 2002.
  14. Clair, E.W.S., C.L. Wagner, A.A. Fasanmade, B.Wang, T. Schaible, A. Kavanaugh and E.C. Keystone. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis – Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthrhitis and Rheumatism 46(6):1451- 1459, 2002.
  15. Crews, KR, C.F. Stewart, D. Jones-Wallace, S.J. Thompson, P.J. Houghton, R.L. Heideman, M. Fouladi, D.C.Bowers, M.M. Chintagumpala and A. Gajjar. Altered Irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clinical Cancer Research 8(7):2202-2209, 2002.
  16. Di Paolo, A., R. Danesi, F. Vannozzi, A. Falcone, E. Mini, L. Cionini, T. Ibrahim, D. Amadori and M. Del Tacca. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clinical Pharmacological Therapy 72(6):627-637, 2002.
  17. Eder, J.P., J.G. Supko, J.W. Clark, T.A. Puchalski, R. Garcia-Carbonero, D.P. Ryan, L.N. Shulman, J. Proper, M. Kirvan, B. Rattner, S. Connors, M.T. Keogan, M.J. Janicek, W.E. Fogler, L. Schnipper, N. Kinchla, C. Sidor, E. Phillips, J. Folkman and D.W. Kufe. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. Journal of Clinical Oncology 20(18):3772- 3784, 2002.
  18. Egorin, M.J., T.R. Lagattuta, D.R. Hamburger, J.M. Covey, K.D. White, S.M. Musser and J.L. Eiseman. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)- 17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemotherapy and Pharmacology 49(1):7-19, 2002.
  19. Fernandez H.F., H.T. Tran, F. Albrecht, S. Lennon, H. Caldera and M.S. Goodman. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biology of Blood and Marrow Transplantation 8(9):486-492, 2002.
  20. Fletcher, C.V., P.L. Anderson, T.N. Kakuda, T.W. Schacker K. Henry C.R. Gross and R.C. Brundage. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16(4):551-560, 2002.
  21. Freyer, G. P. Hennebert, A. Awada, T. Gil, J. Kerger, J. Selleslags, C. Brassinne, M. Piccart and D. de Valeriola. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients. Clinical Cancer Research 8(1):95-102, 2002.
  22. Furman, W.L., C.F. Stewart, M. Kirstein, J.L. Kepner, M.L. Bernstein, F. Kung, T.J.Vietti, C.P. Steuber, D.L. Becton, S. Baruchel and C. Pratt. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A Pediatric Oncology Group study. Journal of Clinical Oncology 20(6):1617-1624, 2002.
  23. Garner, S.S., D.B. Wiest, J.W. Bradley and D.M. Habib. Two administration methods for inhaled salbutamol in intubated patients. Archives of Disease in Childhood 87(1):49-53, 2002.
  24. Graham, G., S. Gupta and L. Aarons. Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data. Journal of Pharmacokinetics and Pharmacodynamics 29(1):67-88, 2002.
  25. Groninger, E., T. Meeuwsen-de Boer, P. Koopmans, D.U. Ges W.D. Sluiter, A. Veerman, W. Kamps and S. de Graaf. Pharmacokineties of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatric Research 52(1):113-118, 2002.
  26. Hamilton A., L. Biganzoli, R. Coleman, L. Mauriac, P. Hennebert, A. Awada, M. Nooij, L. Beex, M. Piccart, I. Van Hoorebeeck, P. Bruning and D. de Valeriola. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx (R), Doxil (R)) at a 6-week interval in patients with metastatic breast cancer. Annals of Oncology 13(6):910-918, 2002.
  27. Herbst, R.S., K.R. Hess, H.T. Tran, J.E. Tseng, N.A. Mullani, C. Charnsangavej, T. Madden, D.W. Davis, D.J. McConkey, M.S. OReilly, L.M. Ellis, J. Pluda, W.K. Hong and J.L. Abbruzzese. Phase I study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology 20(18):3792-3803, 2002.
  28. Hossain, M.M., J.J. Coull, G.L. Drusano, and D.M.Margolis. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine and tenofovir. Antiviral Research 55(1):41-52, 2002.
  29. Jellifee, R.W., M. Macchi-Andanson, B. Charpiat, C. Ducerf, J. Baulieux and N. Fourcade. Through level of tacrolimus Commentary. Therapeutic Drug Monitoring 24(4):573-574, 2002.
  30. Johansen, M.J., N. Thapar, R.A. Newman, and T. Madden. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models. Journal of Experimental Therapeutics and Oncology 2(3):163, 2002.
  31. Kang, W.K. and M.Weiss. Digoxin uptake, receptor heterogeneity, and inotropic response in the isolated rat heart: A comprehensive kinetic model. Journal of Pharmacology and Experimental Therapeutics 302(2):577-583, 2002.
  32. Konsil, J., S. Dechasathian, D.H. Mason and R.E. Stevens. Reanalysis of carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. Journal of Pharmaceutical Science and Technology 5(2):169-75, 2002.
  33. Krzyzanski, W. and W.J. Jusko. Multiple-pool cell lifespan model of hematologic effects of anticancer agents. Journal of Pharmacokinetics and Pharmacodynamics 29(4):311-337, 2002.
  34. Lacayo, N.J, B.L. Lum, D.L. Becton, H. Weinstein, Y.Ravindranath, M.N. Chang MN, L. Bomgaars, S.J. Lauer, B.I. Sikic and G.V. Dahl. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16(5):920-927, 2002.
  35. Leger, F., J. Debord, Y. Le Meur, A. Rousseau, M. Buchler, G. Lachatre, G. Paintaud and P. Marquet. Maximum a posteriori Bayesian estimation of oral cyclosporine pharmacokinetics in patients with stable renal transplants. Clinical Pharmacokinetics 41(1):71-80, 2002.
  36. Leggas, M., C.F. Stewart, M.H. Woo, M. Fouladi, P.J. Cheshire, J.K. Peterson, H.S. Friedman, C. Billups and P.J. Houghton. Relation between irofulven (MGI-114) sys- temic exposure and tumor response in human solid tumor Xenografts. Clinical Cancer Research 8(9):3000-3007, 2002.
  37. Li, H.S., G.M.L. Meno-Tetang, K.J. Chiba, N. Arima, P. Heining andW.J. Jusko. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. Journal of Pharmacology and Experimental Therapeutics 301(2):519-526, 2002.
  38. Liao, W.H., K. Lange, M. Bergsneider and S.C. Huang. Optimal design in dynamic PET data acquisition: A new approach using simulated annealing and component-wise metropolis updating. IEEE Transactions on Nuclear Science 49(5):2291-2296, 2002.
  39. Lucksiri, A., M.K. Scott, B.A. Mueller, R.J. Hamburger and K.M. Sowinski. CAHP- 210 dialyzer influence on intra-dialytic vancomycin removal. Nephrology Dialysis Transplantation 17(9):1649-1654, 2002.
  40. Ma, M.K., H.L. McLeod, P. Westervelt and P.M. Fracasso. Pharmacokinetic study of infusional valspodar. Journal of Clinical Pharmacology 42(4):412-418, 2002.
  41. Magee, M.H., R.A. Blum, C.D. Lates and W.J. Jusko. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. British Journal of Clinical Pharmacology 53(5):474-484, 2002.
  42. Mager, D.E. and W.J. Jusko. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharmaceutical Research 19(10):1537-1543, 2002.
  43. Maring, J.G., A.B.P. van Kuilenburg, J. Haasjes, H. Piersma, H.J.M. Groen, D.R.A. Uges, A.H. Van Gennip and E.G.E. De Vries. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. British Journal of Cancer 86(7):1028-1033, 2002.
  44. Nguyen, L., B. Tranchand, C. Puozzo and P. Variol. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. British Journal of Clinical Pharmacology 53(5):459-468, 2002.
  45. Ostergaard D., M.R. Gatke, H. Berg, S.N. Rasmussen and J. Viby-Mogensen. The pharmacodynamics and pharmacokinetics of mivacurium in children. Acta Anaesthesiologica Scandinavica 46(5):512-518, 2002.
  46. Paladino, J.A., L.D. Gudgel, A. Forrest and M.S. Niederman. Cost-effectiveness of IV-to-oral switch therapy Azithromycin vs cefuroxime with or without erythromycin for the treatement of community-acquired pneumonia. Chest 122(4):1271-1279, 2002.
  47. Panetta J.C., Y. Yanishevski, C.H. Pui, J.T. Sandlund, J. Rubnitz, G.K. Rivera, R. Ribeiro, W.E. Evans and M.V. Relling. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 50(5):419-428, 2002.
  48. Panetta J.C., A. Wall, C.H.Pui, M.V. Relling and W.E.Evans. Methotrexate intracellular disposition in acute lymphoblastic leukemia: A mathematical model of gammaglutamyl hydrolase activity. Clinical Cancer Reseach 8(7):2423-2429, 2002.
  49. Panetta, J.C., M. Wilkinson, C.H. Pui and M.V. Relling. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. Journal of Pharmacokinetics and Pharmacodynamics 29(2):171-188, 2002.
  50. Pereira A.S., L.M. Smeaton J.G. Gerber, E.P. Acosta EP, S. Snyer, S.A. Fiscus, R.R. Tidwell, R.M. Gulick, R.L. Murphy and J.J. Eron. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group Study 850). Journal of Infectious Diseases 186(2):198-204, 2002.
  51. Perlstein I., D. Stepensky, W. Krzyzanski and A. Hoffman. A signal transduction pharmacodynamic model of the kinetics of the parasymphathomimetic activity of low-dose scopolamine and atropine in rats. Journal of Pharmaceutical Sciences 91(12):2500- 2510, 2002.
  52. Pillonetto, G., G. Sparacino, P. Magni, R. Bellazzi and C. Cobelli. Minimal model SI= 0 problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence intervals. American Journal of Physiology-Endocrinology and Metabolism 282(3):E564- E573, 2002.
  53. Ramakrishnan, R., D.C. DuBois, R.R. Almon, N.A. Pyszczynski and W.J. Jusko. Fifth-generation model for corticosteroid pharmacodynamics: Application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. Journal of Pharmacokinetics and Pharmacodynamics 29(1):1-24, 2002.
  54. Ramakrishnan, R., D.C. Dubois, R.R. Almon, N.A. Pyszczynski andW.J. Jusko. Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. Journal of Pharmacology and Experimental Therapeutics 300(1):245-256, 2002.
  55. Ramanathan, M. PA dispersion model for cellular signal transduction cascades. Pharmaceutical Research 19(10):1544-1548, 2002.
  56. Rousseau, A., C. Sabot, N. Delephine, G. Delephine, J. Debord, G. Lachatre and P. Marquet. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localized osteosarcoma. Clinical Pharmacokinetics 41(13):1095-1104, 2002.
  57. Ruiz-Balaguer, N., A.Nacher, V.G.Casabo and M.M.Sanjuan MM. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. International Journal of Pharmaceutics 234(1-2):101-111, 2002.
  58. Russel, J.A., H.T. Tran, D. Quinlan, A. Chaudhry, P. Duggan, C. Brown, D. Stewart, J.D. Ruether, D. Morris, S. Gluck, E. Gyonyor and B.S. Andersson. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biology of Blood and Marrow Transplantation 8(9):468-476, 2002.
  59. Sandor, V., S. Bakke, R.W. Robey, M.H. Kang, M.V. Blagosklonny, J. Bender, R. Brooks, R.L. Piekarz, E. Tucker, W.D. Figg, K.K. Chan, B. Goldspiel, A.T. Fojo, S.P. Balcerzak and S.E. Bates. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clinical Cancer Research 8(3):718-728, 2002.
  60. Schoemaker, N.E., R.A.A. Mathot, P. Schoffski, H. Rosing, J.H.M. Schellens and J.H. Beijnen. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemotherapy and Pharmacology 50(6):514-517, 2002.
  61. Schwartzberg, L.S., I. Petak, C. Stewart, P.K. Turner, J. Ashley, D.M. Tillman, L. Douglas, M. Tan, C. Billups, R. Mihalik, A. Weir, K. Tauer, S. Shope and J.A. Houghton. Modulation of the fas signaling pathway by IFN-gamma in therapy of colon cancer: Phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clinical Cancer Research 8(8):2488-2498, 2002.
  62. Siebes, M., S.A.J. Chamuleau, M. Meuwissen, J.J. Piek and J.A.E. Spaan. Influence of hemodynamic conditions of fractional flow reserve: parametric analysis of underlying model. American Journal of Physiology-Heart and Circulatory Physiology 283(4):1462-1470, 2002.
  63. Sirisuth, N., L.L. Augsburger and N.D. Eddington. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharmaceutics and Drug Disposition 23(1):1-8, 2002.
  64. Stepensky, D., M. Friedman, I. Raz and A. Hoffman. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metabolism and Disposition 30(8):861-868, 2002.
  65. Suarez-Kurtz, G., F.M. Ribeiro, R.C.E. Estrela, F.L. Vicente and C.J. Struchiner. Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4- methylaminoantipyrine, an active metabolite of dipyrone. Brazilian Journal of Medical and Biological Research 34(11):1475-1485, 2002.
  66. Tam, V.H., P.S. McKinnon, R.L. Akins, M.J. Rybak and G.L. Drusano. Pharmacodynamics of cefepime in patients with Gram-negative infections. Journal of Antimicrobial Chemotherapy 8(9):425-428, 2002.
  67. van Kesteren, C., R.A.A. Mathot, E. Raymond, J.P. Armand, P. Fumoleau, C. Punt, M. Ravie, J. Wanders, J.H. Beijnen and J.H.M. Schellens. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). British Journal of Clinical Pharmacology 54(5):463-471, 2002.
  68. van Kesteren, C., R.A.A. Mathot, L. Lopez-Lazaro, E. Cvitkovic, A. Taamma, J.M. Jimeno, C. Guzman*, J.H.M. Schellens, J.L. Misset, E. Brain, M.J.X. Hillebrand, H. Rosing and J.H. Beijnen. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemotherapy and Pharmacology 48(6):459-466, 2002.
  69. Weiss, M., K. Roelsgaard, D. Bender and S. Keiding. Determinants of [N-13]ammonia kinetics in hepatic PET experiments: A minimal recirculatory model. European Journal of Nuclear Medicine and Molecular Imaging 29(12):1648-1656, 2002.
  70. Weiss, M. and W.K. Kang WK. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: Pharmacokinetic/pharmacodynamic modeling. Journal of Pharmacology and Experimental Therapeutics 300(2):688-694, 2002.
  71. Westervelt, P., J.L. Pollock, K.M. Oldfather, M.J. Walter, M.K. Ma, A. Williams, J.F. DiPersio and T.J. Ley TJ. Adaptive immunity cooperates with liposomal all-transretinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 99(14):9468-9473, 2002.
  72. Woo, S.K., W.K. Kang and K.I. Kwon. Pharmacokinetic and pharmacodynamic modeling of the anti-platelet and cardiovascular effects of cilostazol in healthy humans. Clinical Pharmacology and Therapeutics 71(4):246-252, 2002.
  73. Yen, Y., W. Chow, L. Leong, K. Margolin, R. Morgan, J. Raschko, S. Shibata, G. Somlo, P. Twardowski, P. Frankel, J. Longmate, T. Synold, E.M. Newman, H.J. Lenz, D. Gandara and J.H. Doroshow. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California cancer consortium trial. Cancer Chemotherapy and Pharmacology 50(5):353-359, 2002.
  74. Zamboni, W.C., A.C. Gervais, M.J. Egorin, J.H.M. Schellens, D.R. Hamburger, B.J. Delauter, A. Grim, E.G. Zuhowski, D. Pluim, D.M. Potter and J.L. Eiseman. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clinical Cancer Research 8(9):2992-2999, 2002.